--- title: Telemedicine for Early Detection of Cytokine Release Syndrome and Neurotoxicity nct_id: NCT04503538 overall_status: WITHDRAWN phase: NA sponsor: Wake Forest University Health Sciences study_type: INTERVENTIONAL primary_condition: Large B-cell Lymphoma canonical_url: "https://parkinsonspathways.com/agent/trials/NCT04503538.md" clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT04503538" ct_last_update_post_date: 2020-10-23 last_seen_at: "2026-05-12T06:43:54.613Z" source: ClinicalTrials.gov (mirrored, no enrichment) --- # Telemedicine for Early Detection of Cytokine Release Syndrome and Neurotoxicity **Official Title:** Telemedicine for Early Detection of Cytokine Release Syndrome and Neurotoxicity Following CAR-T Infusion on an Outpatient Basis **NCT ID:** [NCT04503538](https://clinicaltrials.gov/study/NCT04503538) ## Key Facts - **Status:** WITHDRAWN - **Why Stopped:** Principal investigator decided not to pursue trial - **Phase:** NA - **Study Type:** INTERVENTIONAL - **Target Enrollment:** 0 - **Lead Sponsor:** Wake Forest University Health Sciences - **Conditions:** Large B-cell Lymphoma, Diffuse Large B Cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma - **Start Date:** 2020-12 - **Completion Date:** 2023-11 - **CT.gov Last Update:** 2020-10-23 ## Brief Summary The purpose of this research is to replace one of participants' outpatient chimeric antigen receptor T-cell (CAR-T) therapy follow up visits with a virtual or "telemedicine" visit. The telemedicine visit will use an electronic tablet with a camera and a microphone that allows participants to communicate with their physicians and nurses. Participants will be provided with the necessary equipment to complete these visits. ## Detailed Description Primary Objective: To determine feasibility of telemedicine for outpatient cytokine release syndrome and neurotoxicity assessment (how many telemedicine visits successfully completed per patient) Secondary Objective(s) * To determine how many times a telemedicine visit triggered an action (inpatient admission/ outpatient observation status) * To determine how many patients were detected to have cytokine release syndrome and/or neurotoxicity based on their telemedicine visit ## Eligibility - **Minimum age:** 18 Years - **Sex:** ALL - **Healthy Volunteers:** No ``` Inclusion Criteria: * Patients must have histologically confirmed relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma, and DLBCL arising from of follicular lymphoma * Age ≥ 18 years * ECOG or Karnofsky performance status of ≤ 2 * Patients must have a caregiver(s) with them 24 hours a day for the first 30 days after CAR-T cell infusion * Patients must stay within a 30-minute distance from the cancer center * Patients must have access to wifi network or a cellular network * Patients and caregiver(s) participating in patient's care must attend the education session for outpatient CAR-T and demonstrate competency to collect vital signs with equipment provided * Must have the ability to understand and the willingness to sign an IRB-approved informed consent document (either directly or via a legally authorized representative). Exclusion Criteria: * Patients who have acute lymphoblastic leukemia/lymphoma * Patients who have a high tumor burden (\> 10 cm largest mass) have a high risk of CRS who will receive CAR-T as an inpatient * Patient or caregiver unable to understand and follow English language * Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. ``` ## Arms - **CAR-T cell therapy and Telemedicine** (OTHER) — All outpatient CAR-T patients will require assessments for cytokine release syndrome and neurotoxicity three times daily (every 8 hours) ## Interventions - **Telemedicine visit** (OTHER) — Participants will be provided with a Wifi-and cellular enabled electronic tablet. Additionally, participants will receive a kit that contains a thermometer, a blood pressure monitoring cuff, and a pulse oximeter (to measure oxygen saturation level). Participants will attend an educational session to learn how the telemedicine visit works. Caregivers should attend with participants and will be trained to take temperatures, blood pressures, and oxygen saturation levels. Participants will also be asked to complete a test telehealth visit. ## Primary Outcomes - **Number of Successfully Completed Telemedicine Visits** _(time frame: 3 years)_ — To determine feasibility of telemedicine for outpatient cytokine release syndrome and neurotoxicity assessment. Investigators will consider telemedicine feasible in this population if at least 13 of the 15 patients successfully complete 80% of telemedicine visits. A visit will be considered successful if all measurements are recorded OR if the visit is interrupted because the participant needs to come into the CAR-T unit for assessment. If a patient is admitted, then the 80% benchmark will be calculated based on the number of days the patient was outpatient at 11 pm. The proportion meeting the 80% benchmark will be reported along with an exact 95% confidence interval. ## Secondary Outcomes - **Number of Times a Telemedicine Visit Triggered Action** _(time frame: 3 years)_ - **Number of Patients to Have Cytokine Release Syndrome** _(time frame: 3 years)_ - **Number of Patients to Have Neurotoxicity** _(time frame: 3 years)_ ## Recent Field Changes (last 30 days) - `status.overallStatus` — added _(2026-05-12)_ - `status.whyStopped` — added _(2026-05-12)_ - `status.primaryCompletionDate` — added _(2026-05-12)_ - `status.completionDate` — added _(2026-05-12)_ - `status.lastUpdatePostDate` — added _(2026-05-12)_ - `design.phases` — added _(2026-05-12)_ - `design.enrollmentCount` — added _(2026-05-12)_ - `eligibility.criteria` — added _(2026-05-12)_ - `eligibility.minAge` — added _(2026-05-12)_ - `eligibility.sex` — added _(2026-05-12)_ - `outcomes.primary` — added _(2026-05-12)_ - `outcomes.secondary` — added _(2026-05-12)_ - `armsInterventions.arms` — added _(2026-05-12)_ - `armsInterventions.interventions` — added _(2026-05-12)_ - `sponsor.lead` — added _(2026-05-12)_ - `results.hasResults` — added _(2026-05-12)_ --- *Canonical: https://parkinsonspathways.com/agent/trials/NCT04503538.md* *Source data (authoritative): https://clinicaltrials.gov/study/NCT04503538* *This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*